Frequent promoter methylation of HOXD10 in endometrial carcinoma and its pathological significance

Fan Yang, Dongchen Liu, Yupeng Deng, Jun Wang, Shuyu Mei, Shuang Ge, Hailing Li, Cuijuan Zhang, Tingguo ZhangOncology 2020 · DOI

Abstract

Homeobox D 10 (HOXD10) is a tumor suppressor gene (TSG) involved in cell differentiation and morphogenesis. This study investigated its promoter methylation status and protein expression in endometrial cancer (EC). Samples from 62 EC patients (50 endometrioid adenocarcinoma [EA], 12 mucinous endometrial carcinoma [MEC]) and 70 non-cancerous controls were analyzed. HOXD10 promoter methylation was significantly more frequent in cancer samples ($P < 0.001$). Immunohistochemistry (IHC) confirmed protein downregulation in EC ($P < 0.001$), which correlated negatively with methylation status ($P < 0.05$). Notably, MEC samples showed significantly lower HOXD10 expression than EA samples ($P < 0.001$). Treatment with 5-Aza-2-deoxycytidine partially reversed silencing in the Ishikawa cell line. These results suggest that epigenetic silencing of HOXD10 contributes to EC tumorigenesis and that HOXD10 protein levels may serve as a useful biomarker to distinguish EA from MEC.

Introduction

Endometrial carcinoma (EC) is a leading gynecological malignancy. A significant clinical challenge lies in distinguishing between its pathological subtypes, particularly endometrioid adenocarcinoma (EA) and the rarer, more aggressive mucinous endometrial carcinoma (MEC). MEC is often associated with older age and a higher likelihood of lymphatic metastasis, but its histological boundaries with EA can be ambiguous.

This study investigates the role of HOXD10, a master regulator of cell differentiation, in EC. We hypothesized that HOXD10 is epigenetically silenced via promoter hypermethylation, acting as a driver of the disease and providing a potential diagnostic tool to differentiate these subtypes.

Methods

The study utilized a clinical dataset of 132 paraffin-embedded tissue blocks, including 62 cancer cases (50 EA, 12 MEC) and 70 non-cancerous controls (hyperplasia). The role of HOXD10 was validated through several modalities:

  • Methylation-Specific PCR (MSP): To determine the methylation status of the HOXD10 promoter in clinical tissue samples.
  • Immunohistochemistry (IHC): To visualize and semi-quantitatively score HOXD10 protein expression in tissue sections.
  • Cell Line Validation: The Ishikawa (EC) cell line was treated with 5-Aza-2'-deoxycytidine (5-Aza-CdR), a demethylating agent, to observe if gene silencing could be reversed.
  • Western Blotting: Used to quantify protein expression changes following 5-Aza-CdR treatment.

Results

HOXD10 Promoter Hypermethylation

MSP analysis revealed that HOXD10 promoter methylation was significantly more frequent in cancer samples (69.4%, 43/62) compared to non-cancerous controls (15.7%, 11/70; $P < 0.0001$). This confirms that epigenetic silencing via hypermethylation is a common event in EC development.

Figure 1: MSP analysis showing the methylation (M) and unmethylation (U) status of HOXD10 in tumor (T) vs. non-cancerous (N) tissues.

Protein Downregulation and Subtype Specificity

IHC staining confirmed that HOXD10 protein expression was significantly lower in cancer cases ($P < 0.0001$). A striking finding for diagnostics was the difference between subtypes: 0% of MEC samples expressed the HOXD10 protein, whereas 50% of EA samples still showed positive staining ($P = 0.0010$). This suggests that a total lack of HOXD10 protein is a strong indicator of the mucinous subtype.

Figure 2: Immunohistochemical staining of HOXD10 in endometrial tissues, showing differential expression patterns.

Reversibility of Silencing

In the Ishikawa cell line, treatment with the demethylating agent 5-Aza-CdR significantly increased HOXD10 protein levels in a dose-dependent manner ($P < 0.01$). This confirms that the downregulation is indeed epigenetic (due to methylation) rather than a permanent genetic mutation, suggesting potential for epigenetic therapies.

Discussion

The findings demonstrate that epigenetic silencing of HOXD10 contributes to the tumorigenesis of EC. While both EA and MEC exhibit high rates of DNA methylation, the significant difference in protein expression levels indicates that HOXD10 may be a valuable biomarker for distinguishing between these two lesions.

The primary limitation of this study is the small sample size for the MEC subtype (n=12). Larger cohorts are required to confirm HOXD10's reliability as a clinical biomarker. Future research should also explore the specific downstream signaling pathways through which HOXD10 exerts its suppressive effects in endometrial tissues.

Summary updated

Abstract

Homeobox D 10 (HOXD10) is important in cell differentiation and morphogenesis and serves as a tumor suppressor gene (TSG) in a number of malignancies. The present study investigated its promoter methylation status and association with the clinicopathological features of endometrial cancer (EC), and measured HOXD10 protein expression levels. EC samples (n=62), including 50 endometroid adenocarcinoma (EA) and 12 mucinous endometrial carcinoma samples (EC) and 70 non-cancerous samples were collected. All samples were evaluated for the methylation status of several TSGs, including HOXD10, using methylation-specific PCR. HOXD10 expression level was evaluated using immunohistochemistry. 5-Aza-2-deoxycytidine treatment was performed in the EC cell line Ishikawa to observe the change in HOXD10 expression levels. HOXD10 promoter methylation was more frequent in cancer samples (P<0.001). Downregulation of HOXD10 in EC samples was confirmed at the protein level using immunohistochemistry (P<0.001) and immunohistochemical staining was negatively associated with methylation status (P<0.05). Less HOXD10 protein was expressed in MEC compared with EA samples (P<0.001). The HOXD10 promoter was hypermethylated in both EA and MEC, causing decreased HOXD10 protein expression levels in EC cells. HOXD10 expression levels were partially reversed by 5-Aza-2-deoxycytidine treatment. The results of the present study demonstrated that epigenetic silencing of HOXD10 putatively contributed to the tumorigenesis of EA. Although there was no significant difference in HOXD10 methylation between EA and MEC, HOXD10 protein expression levels differed between these two diseases, indicating that it may be a useful protein biomarker for distinguishing between these two lesions.
BibTeX
@inproceedings{yang2020frequent,
  author = {Fan Yang and Dongchen Liu and Yupeng Deng and Jun Wang and Shuyu Mei and Shuang Ge and Hailing Li and Cuijuan Zhang and Tingguo Zhang},
  title = {{Frequent promoter methylation of HOXD10 in endometrial carcinoma and its pathological significance}},
  booktitle = {Oncology},
  year = {2020},
  doi = {10.3892/ol.2020.11467},
}
Figure